{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:13:50Z","timestamp":1793726030295,"version":"4.6.1"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFE0131700"],"award-info":[{"award-number":["2022YFE0131700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271835"],"award-info":[{"award-number":["82271835"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071813"],"award-info":[{"award-number":["82071813"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cyto.2025.157032","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:12:23Z","timestamp":1758589943000},"page":"157032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The dual role of IL-2 in systemic lupus erythematosus: balancing pro-inflammatory and anti-inflammatory effects"],"prefix":"10.1016","volume":"196","author":[{"given":"Hao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.cyto.2025.157032_bb0005","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: A review","volume":"331","author":"Siegel","year":"2024","journal-title":"Jama"},{"key":"10.1016\/j.cyto.2025.157032_bb0010","article-title":"Systemic lupus erythematosus","volume":"172(11):Itc81-itc96","author":"Kiriakidou","year":"2020","journal-title":"Ann. Intern. Med."},{"issue":"10441","key":"10.1016\/j.cyto.2025.157032_bb0015","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2025.157032_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109031","article-title":"T cell dysregulation in SLE","volume":"239","author":"Tenbrock","year":"2022","journal-title":"Clin. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2025.157032_bb0025","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cyto.2025.157032_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156588","article-title":"Cytokine and chemokine profiles in women with endometriosis, polycystic ovary syndrome, and unexplained infertility","volume":"178","author":"Omidvar-Mehrabadi","year":"2024","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0035","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1073\/pnas.0903158107","article-title":"Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus","volume":"107","author":"Humrich","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/art.41457","article-title":"Conversion of T follicular helper cells to T follicular regulatory cells by Interleukin-2 through transcriptional regulation in systemic lupus erythematosus","volume":"73","author":"Hao","year":"2021","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.cyto.2025.157032_bb0045","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"4257","key":"10.1016\/j.cyto.2025.157032_bb0050","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1126\/science.181845","article-title":"Selective in vitro growth of T lymphocytes from normal human bone marrows","volume":"193","author":"Morgan","year":"1976","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.cyto.2025.157032_bb0055","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/JLB.2RI0717-278R","article-title":"Biology of IL-2 and its therapeutic modulation: mechanisms and strategies","volume":"103","author":"Mitra","year":"2018","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","article-title":"Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.cyto.2025.157032_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112996","article-title":"IL-2 can signal via chemokine receptors to promote regulatory T cells\u2019 suppressive function","volume":"42","author":"Sun","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.cyto.2025.157032_bb0070","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-med-073118-011031","article-title":"Engineering IL-2 to give new life to T cell immunotherapy","volume":"72","author":"Overwijk","year":"2021","journal-title":"Annu. Rev. Med."},{"issue":"5751","key":"10.1016\/j.cyto.2025.157032_bb0075","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1126\/science.1117893","article-title":"Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors","volume":"310","author":"Wang","year":"2005","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.cyto.2025.157032_bb0080","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/imm.13723","article-title":"The soluble IL-2 receptor \u03b1\/CD25 as a modulator of IL-2 function","volume":"171","author":"Lokau","year":"2024","journal-title":"Immunology"},{"issue":"25","key":"10.1016\/j.cyto.2025.157032_bb0085","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat1482","article-title":"Revisiting IL-2: biology and therapeutic prospects","volume":"3","author":"Abbas","year":"2018","journal-title":"Sci Immunol."},{"issue":"9","key":"10.1016\/j.cyto.2025.157032_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103156","article-title":"Short-term and low-dose IL-2 therapy increases the reduced Treg cells in patients with microscopic polyangiitis","volume":"21","author":"Wu","year":"2022","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.cyto.2025.157032_bb0095","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2478\/rir-2023-0021","article-title":"Low-dose interleukin-2 therapy in systemic lupus erythematosus","volume":"4","author":"La Cava","year":"2023","journal-title":"Rheumatol Immunol Res."},{"issue":"11","key":"10.1016\/j.cyto.2025.157032_bb0100","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ni1263","article-title":"A function for interleukin 2 in Foxp3-expressing regulatory T cells","volume":"6","author":"Fontenot","year":"2005","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0105","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","article-title":"Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics","volume":"10","author":"Dai","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cyto.2025.157032_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.635531","article-title":"Double-edged sword: Interleukin-2 promotes T regulatory cell differentiation but also expands Interleukin-13- and interferon-\u03b3-producing CD8(+) T cells via STAT6-GATA-3 Axis in systemic lupus erythematosus","volume":"12","author":"Kato","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cellimm.2009.03.016","article-title":"Defects of mitogen-activated protein kinase in ICOS signaling pathway lead to CD4(+) and CD8(+) T-cell dysfunction in patients with active SLE","volume":"258","author":"Gang","year":"2009","journal-title":"Cell. Immunol."},{"issue":"526","key":"10.1016\/j.cyto.2025.157032_bb0120","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aap8112","article-title":"Interleukin-2 shapes the cytotoxic T cell proteome and immune environment-sensing programs","volume":"11","author":"Rollings","year":"2018","journal-title":"Sci. Signal."},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0125","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1172\/JCI40178","article-title":"CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production","volume":"120","author":"Peperzak","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.cyto.2025.157032_bb0130","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.4049\/jimmunol.168.11.5566","article-title":"Essential role for IL-2 in the regulation of antiviral extralymphoid CD8 T cell responses","volume":"168","author":"D\u2019Souza","year":"2002","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.cyto.2025.157032_bb0135","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/ard.49.9.690","article-title":"Natural killer cell activity in Sj\u00f6gren\u2019s syndrome and systemic lupus erythematosus: stimulation with interferons and interleukin-2 and correlation with immune complexes","volume":"49","author":"Struyf","year":"1990","journal-title":"Ann. Rheum. Dis."},{"issue":"5813","key":"10.1016\/j.cyto.2025.157032_bb0140","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/291335a0","article-title":"Interleukin-2 augments natural killer cell activity","volume":"291","author":"Henney","year":"1981","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.cyto.2025.157032_bb0145","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1084\/jem.20122462","article-title":"IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells","volume":"210","author":"Gasteiger","year":"2013","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0150","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood-2002-08-2602","article-title":"IL-4 synergistically enhances both IL-2- and IL-12-induced IFN-gamma expression in murine NK cells","volume":"102","author":"Bream","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10238-021-00726-8","article-title":"Increased TIM-3(+)PD-1(+) NK cells are associated with the disease activity and severity of systemic lupus erythematosus","volume":"22","author":"Luo","year":"2022","journal-title":"Clin. Exp. Med."},{"issue":"6","key":"10.1016\/j.cyto.2025.157032_bb0160","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10067-013-2176-8","article-title":"NK cells dysfunction in systemic lupus erythematosus: relation to disease activity","volume":"32","author":"Henriques","year":"2013","journal-title":"Clin. Rheumatol."},{"issue":"11","key":"10.1016\/j.cyto.2025.157032_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0312141","article-title":"Immune complex deposition promotes NK cell accumulation in the kidney","volume":"19","author":"De la Cruz","year":"2024","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.cyto.2025.157032_bb0170","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/jir.2018.0016","article-title":"Interleukin-2 deficiency associated with renal impairment in systemic lupus erythematosus","volume":"39","author":"Shao","year":"2019","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.cyto.2025.157032_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.938556","article-title":"Increased sIL-2R\u03b1 leads to obstruction of IL-2 biological function and Treg cells differentiation in SLE patients via binding to IL-2","volume":"13","author":"Long","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.cyto.2025.157032_bb0180","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.4049\/jimmunol.130.6.2651","article-title":"Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE)","volume":"130","author":"Linker-Israeli","year":"1983","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.cyto.2025.157032_bb0185","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","article-title":"Autoimmunity and organ damage in systemic lupus erythematosus","volume":"21","author":"Tsokos","year":"2020","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.cyto.2025.157032_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/cells8101234","article-title":"IL-2 therapy diminishes renal inflammation and the activity of kidney-infiltrating CD4+ T cells in murine lupus nephritis","volume":"8","author":"Rose","year":"2019","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.cyto.2025.157032_bb0195","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nri1435","article-title":"Tolerance, not immunity, crucially depends on IL-2","volume":"4","author":"Malek","year":"2004","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.cyto.2025.157032_bb0200","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.4049\/jimmunol.1900733","article-title":"Low-dose IL-2 therapy in transplantation, autoimmunity, and inflammatory diseases","volume":"203","author":"Tahvildari","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2025.157032_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102376","article-title":"Treg cells in health and autoimmune diseases: new insights from single cell analysis","volume":"110","author":"Scheinecker","year":"2020","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0210","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","article-title":"Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus","volume":"15","author":"Doglio","year":"2024","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.cyto.2025.157032_bb0215","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/rheumatology\/ken108","article-title":"Altered frequency and migration capacity of CD4+CD25+ regulatory T cells in systemic lupus erythematosus","volume":"47","author":"Lee","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.cyto.2025.157032_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111606","article-title":"Single-cell transcriptome profiling and chromatin accessibility reveal an exhausted regulatory CD4+ T cell subset in systemic lupus erythematosus","volume":"41","author":"Guo","year":"2022","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.cyto.2025.157032_bb0225","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11926-016-0617-5","article-title":"Low-dose IL-2 in the treatment of lupus","volume":"18","author":"Mizui","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0230","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41392-023-01350-6","article-title":"Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE","volume":"8","author":"Zhou","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0235","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1165","article-title":"Efficacy, safety and the lymphocyte subsets changes of low-dose IL-2 in patients with systemic lupus erythematosus: A systematic review and meta-analysis","volume":"12","author":"Su","year":"2024","journal-title":"Immun Inflamm Dis."},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0240","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40744-023-00620-7","article-title":"Efficacy, safety and the lymphocyte subset changes of low-dose IL-2 in patients with autoimmune rheumatic diseases: A systematic review and Meta-analysis","volume":"11","author":"Su","year":"2024","journal-title":"Rheumatol Ther."},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0245","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.cyto.2025.157032_bb0250","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus","volume":"75","author":"von Spee-Mayer","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.cyto.2025.157032_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2024.07.016","article-title":"Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics","volume":"57","author":"Raeber","year":"2024","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.cyto.2025.157032_bb0260","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.immuni.2024.02.001","article-title":"Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer","volume":"57","author":"Shouse","year":"2024","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.cyto.2025.157032_bb0265","article-title":"A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2R\u03b1 strengthens T cell-mediated anti-tumor therapies","volume":"5","author":"Wu","year":"2024","journal-title":"Cell Rep Med"},{"issue":"7","key":"10.1016\/j.cyto.2025.157032_bb0270","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20212391","article-title":"Context-dependent effects of IL-2 rewire immunity into distinct cellular circuits","volume":"219","author":"Whyte","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cyto.2025.157032_bb0275","doi-asserted-by":"crossref","first-page":"1230264","DOI":"10.3389\/fimmu.2023.1230264","article-title":"Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus","volume":"14","author":"Tsai","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0280","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/cei.12629","article-title":"Interleukin-2 treatment reverses effects of cAMP-responsive element modulator \u03b1-over-expressing T cells in autoimmune-prone mice","volume":"181","author":"Ohl","year":"2015","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2025.157032_bb0285","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/cei\/uxac105","article-title":"IL-2-based approaches to Treg enhancement","volume":"211","author":"Harris","year":"2023","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.cyto.2025.157032_bb0290","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.0105-2896.2004.00203.x","article-title":"Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways","volume":"202","author":"Kovanen","year":"2004","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0295","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191247","article-title":"Effects of interleukin-2 in immunostimulation and immunosuppression","volume":"217","author":"Pol","year":"2020","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.cyto.2025.157032_bb0300","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1078-0432.CCR-13-3205","article-title":"Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity","volume":"20","author":"Kennedy-Nasser","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.cyto.2025.157032_bb0305","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2025.157032_bb0310","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-immunol-042617-053352","article-title":"Signaling and function of Interleukin-2 in T lymphocytes","volume":"36","author":"Ross","year":"2018","journal-title":"Annu. Rev. Immunol."},{"issue":"21","key":"10.1016\/j.cyto.2025.157032_bb0315","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1038\/sj.onc.1203523","article-title":"The role of Stat5a and Stat5b in signaling by IL-2 family cytokines","volume":"19","author":"Lin","year":"2000","journal-title":"Oncogene"},{"issue":"510","key":"10.1016\/j.cyto.2025.157032_bb0320","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aan4931","article-title":"IL-2R\u03b2 abundance differentially tunes IL-2 signaling dynamics in CD4(+) and CD8(+) T cells","volume":"10","author":"Smith","year":"2017","journal-title":"Sci. Signal."},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0325","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41467-017-01477-5","article-title":"Critical functions for STAT5 tetramers in the maturation and survival of natural killer cells","volume":"8","author":"Lin","year":"2017","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.cyto.2025.157032_bb0330","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.4049\/jimmunol.2000612","article-title":"Dynamic roles for IL-2-STAT5 Signaling in effector and regulatory CD4(+) T cell populations","volume":"205","author":"Jones","year":"2020","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2025.157032_bb0335","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1073\/pnas.0909384107","article-title":"IL-2\/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25","volume":"107","author":"L\u00e9tourneau","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.cyto.2025.157032_bb0340","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/ni.1995","article-title":"Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5","volume":"12","author":"Yang","year":"2011","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2025.157032_bb0345","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.immuni.2010.08.004","article-title":"Interleukin-2 receptor signaling: at the interface between tolerance and immunity","volume":"33","author":"Malek","year":"2010","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.cyto.2025.157032_bb0350","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1080\/03007995.2022.2065145","article-title":"Low-dose IL-2 therapy limits the reduction in absolute numbers of peripheral lymphocytes in systemic lupus erythematosus patients with infection","volume":"38","author":"Zhang","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0355","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12865-019-0305-0","article-title":"Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17\/Treg cells in refractory SLE patients","volume":"20","author":"Zhao","year":"2019","journal-title":"BMC Immunol."},{"key":"10.1016\/j.cyto.2025.157032_bb0360","doi-asserted-by":"crossref","first-page":"1703842","DOI":"10.1155\/2019\/1703842","article-title":"Correlations of expression levels of a panel of genes (IRF5, STAT4, TNFSF4, MECP2, and TLR7) and cytokine levels (IL-2, IL-6, IL-10, IL-12, IFN-\u03b3, and TNF-\u03b1) with systemic lupus erythematosus outcomes in Jordanian patients","volume":"2019","author":"Uzrail","year":"2019","journal-title":"Biomed. Res. Int."},{"issue":"4","key":"10.1016\/j.cyto.2025.157032_bb0365","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1172\/JCI22854","article-title":"Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV","volume":"115","author":"Juang","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0370","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13075-024-03388-5","article-title":"Predictive biomarkers for low-dose IL-2 therapy efficacy in systemic lupus erythematosus: a clinical analysis","volume":"26","author":"Feng","year":"2024","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.cyto.2025.157032_bb0375","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10875-007-9104-0","article-title":"Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus","volume":"27","author":"Chun","year":"2007","journal-title":"J. Clin. Immunol."},{"issue":"22","key":"10.1016\/j.cyto.2025.157032_bb0380","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.cyto.2025.157032_bb0385","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer","volume":"22","author":"Hernandez","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2025.157032_bb0390","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.kint.2016.09.022","article-title":"IL-2\/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4(+)CD25(+)Foxp3(+) regulatory T cells","volume":"91","author":"Yan","year":"2017","journal-title":"Kidney Int."},{"issue":"11","key":"10.1016\/j.cyto.2025.157032_bb0395","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.2337\/db20-0186","article-title":"Persistent IL-2 receptor Signaling by IL-2\/CD25 fusion protein controls diabetes in NOD mice by multiple mechanisms","volume":"69","author":"Ward","year":"2020","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.cyto.2025.157032_bb0400","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41591-018-0070-2","article-title":"A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism","volume":"24","author":"Trotta","year":"2018","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.cyto.2025.157032_bb0405","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40259-023-00635-0","article-title":"Molecular engineering of Interleukin-2 for enhanced therapeutic activity in autoimmune diseases","volume":"38","author":"Tomasovic","year":"2024","journal-title":"BioDrugs"},{"issue":"4","key":"10.1016\/j.cyto.2025.157032_bb0410","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/annrheumdis-2014-206506","article-title":"Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE","volume":"74","author":"Humrich","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0415","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/S2665-9913(19)30018-9","article-title":"Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-Centre phase 1 and 2a clinical trial","volume":"1","author":"Humrich","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"12","key":"10.1016\/j.cyto.2025.157032_bb0420","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/ard-2022-222501","article-title":"Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial","volume":"81","author":"Humrich","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0425","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41392-022-00887-2","article-title":"Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cyto.2025.157032_bb0430","doi-asserted-by":"crossref","first-page":"1359041","DOI":"10.3389\/fimmu.2024.1359041","article-title":"The efficacy and safety of short-term and low-dose IL-2 combined with tocilizumab to treat rheumatoid arthritis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.157032_bb0435","article-title":"Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: A randomized controlled trial","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.cyto.2025.157032_bb0440","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.41451","article-title":"Efficacy and safety of low-dose interleukin 2 for primary Sj\u00f6gren syndrome: A randomized clinical trial","volume":"5","author":"He","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/j.cyto.2025.157032_bb0445","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.cyto.2025.157032_bb0450","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.cji.0000211315.21116.07","article-title":"Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma","volume":"30","author":"Lopes de Menezes","year":"2007","journal-title":"J. Immunother."},{"key":"10.1016\/j.cyto.2025.157032_bb0455","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clim.2018.11.002","article-title":"Natural and modified IL-2 for the treatment of cancer and autoimmune diseases","volume":"206","author":"Mizui","year":"2019","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.cyto.2025.157032_bb0460","article-title":"Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus","volume":"5","author":"Fanton","year":"2022","journal-title":"J Transl Autoimmun."},{"issue":"2","key":"10.1016\/j.cyto.2025.157032_bb0465","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003500","article-title":"Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1-phase 2a study","volume":"10","author":"Barde","year":"2024","journal-title":"RMD Open"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625001796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625001796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T09:18:47Z","timestamp":1762593527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466625001796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":93,"alternative-id":["S1043466625001796"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2025.157032","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The dual role of IL-2 in systemic lupus erythematosus: balancing pro-inflammatory and anti-inflammatory effects","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2025.157032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"157032"}}